US Regenerative Medicine Market Overview
US Regenerative Medicine Market Size was valued at USD 4.1 Billion in 2022. The regenerative medicine market industry is projected to grow from USD 5.3 Billion in 2023 to USD 39.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 28.50% during the forecast period (2023 - 2032). The primary market drivers of the market's expansion include rising consumer knowledge of and demand for the use of gene treatments, tissue engineering, and stem cells. The market for regenerative medicine has grown in the United States due to the increasing number of individuals in need of these treatments.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
US Regenerative Medicine Market Trends
- Growing consumer demand for cancer therapy products to boost the market growth
The market is being stimulated by rising product demand for cancer therapy. Uncontrolled cell development in cancer frequently results in tissue damage that can be repaired using regenerative therapy. Through the application of regenerative medicine, specific therapeutics that can restore tissues damaged by cancer or adverse effects from chemotherapy can be developed. It seeks to reduce the crippling side effects of conventional cancer treatment, improving the general quality of life of patients. Through the manipulation of the tumor microenvironment, these methods may be able to slow the advancement of cancer.
Additionally, by mending immune cells or tissues damaged during therapy, it enhances newly developed cancer immunotherapies. Thorough investigation and clinical studies examine the possibilities of regeneration treatments for different kinds of cancer, which promotes industry expansion. Research and development funding is drawn to regenerative treatments due to its potential to completely transform the treatment of cancer. Furthermore, the need for regenerative medicine in cancer care is fueled by the growing incidence of cancer and the search for more efficient, patient-friendly treatments, which has led to a substantial expansion of the market.
The market is being driven by the quick developments in immunotherapy. A branch of regenerative medicine called immunotherapy uses the body's immune system to combat illnesses like cancer and autoimmune diseases. Immunotherapies, which improve the body's capacity to identify and fight cancer cells, have transformed the treatment of cancer. Examples of these medicines include immune checkpoint inhibitors and CAR-T cell therapy. Improvements in immunotherapy support the trend toward precision medicine by enabling more individualized treatment options. Patient outcomes are improved because they frequently have less severe side effects than conventional treatments like radiation therapy and chemotherapy.
In an effort to improve treatment outcomes and broaden the application of regenerative medicine, researchers are investigating the integration of immunotherapies with regeneration techniques. In addition, sturdy clinical trials and research projects concentrate on improving immunotherapies, promoting advancements in the area. Applications of immunotherapies are being researched for conditions other than cancer, such as organ transplantation, infectious infections, and autoimmune disorders. Significant research and development funding is drawn to immunotherapy due to its potential to revolutionize the treatment of disease. Immunotherapies are becoming more and more popular, and this is helping the industry expand and patients become more advocates. Thus, driving the regenerative medicine market revenue.
US Regenerative Medicine Market Segment Insights
US Regenerative Medicine Product Insights
The US Regenerative Medicine market segmentation, based on product includes Gene Therapy, Cell Therapy, Stem Cell Therapy (Autologous Therapy, Allogenic Therapy), Cord Blood/Progenitor Cell Therapies, Cell-Based Immunotherapy Products, Tissue Engineering, Scaffolds, Hydrogels, Collagen, and Others. The cell therapy segment dominated the market mostly. The main reason for the segment's rise is the ongoing progress made in stem cell therapies to broaden its use in more recent illness categories. The segment will have substantial growth opportunities as new treatments for neuro-vegetative disorders and ocular ailments are developed. Furthermore, the potential of stem cells to treat heart failure and the numerous studies being conducted to provide such treatments will spur profitable market expansion in the future. Tissue engineering's benefits in using cells, scaffolds, and growth factors to create damaged tissues allowed it to have the second-largest market share.
US Regenerative Medicine Application Insights
The US Regenerative Medicine market segmentation, based on application, includes Musculoskeletal, Oncology, Wound Care, Dental Indications, Retinal Indications, and Other Applications. The musculoskeletal category generated the most income. The increasing incidence of orthopedic disorders is a significant contributing factor to this rise. The growing number of elderly people exacerbates this. The number of Americans 65 and older is predicted to almost double from 52 million in 2018 to 95 million in 2060, according to the Population Reference Bureau.
Figure 1: US Regenerative Medicine Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
US Regenerative Medicine Country Insights
Government programs, healthcare sector investments, and private funding for infrastructure development can all be used to examine the US market for regenerative medicine. Some of the causes can also be linked to the nation's growing disposable income and willingness to spend on healthcare. Further driving the regenerative medicine market's expansion is the government's and private research organizations' favorable inclinations to spend in and support R&D. In 2020, for instance, the U.S. Department of Health and Human Services unveiled "A New Vision," which acknowledges regenerative medicine as the forefront of healthcare.
Moreover, the growing use of gene treatments, tissue engineering, and stem cell technologies, as well as technological developments in regenerative medicine, are the main drivers of the US regenerative medicine market's expansion. In the United States, congenital heart problems are predicted to impact at least 40,000 infants annually, according to the Heart Disease & Stroke Statistical Fact Sheet 2020. About 25% of these, or 2.4 out of every 1,000 live births, need medical attention within the first year of life. Furthermore, there will likely be 12.1 million cases of atrial fibrillation in the US by 2030, according to the Centers for Disease Control and Prevention (CDC).
US Regenerative Medicine Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the regenerative medicine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, regenerative medicine industry must offer cost-effective items.
Major players in the regenerative medicine market are attempting to increase market demand by investing in research and development operations includes Biogen (US), Amgen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Vericel Corporation (US), MiMedx (US), Organogenesis Inc. (US), Medtronic plc (US), BioRestorative Therapies, Inc (US), bluebird bio, Inc. (US), and Athersys, Inc. (US).
Key Companies in the US regenerative medicine market include
- Biogen (US)
- Sarepta Therapeutics, Inc. (US)
- Gilead Sciences, Inc. (US)
- Amgen, Inc. (US)
- Vericel Corporation (US)
- MiMedx (US)
- Organogenesis Inc. (US)
- Medtronic plc (US)
- BioRestorative Therapies, Inc (US)
- bluebird bio, Inc. (US)
- Athersys, Inc. (US)
US Regenerative Medicine Industry Developments
April 2022:The U.S. Food and Drug Administration (FDA) has designated Autolus Therapeutics plc's lead gene therapy, obecabatagene autoleucel, a CD19-directed autologous chimeric antigen receptor T therapy being studied in the ongoing FELIX Phase 2 study of leukemia, as Regenerative Medicine Advanced Therapy. This announcement was made by the company.
May 2021:The FDA in the United States approved Breyanzi for Bristol Myers Squibb. Adults with large B-cell lymphoma (LBCL) that has relapsed or is refractory (R/R) are eligible to use the medicine. The launch of the new product expanded the company's clientele and range of offerings.
US Regenerative Medicine Market Segmentation
US Regenerative Medicine Product Outlook
- Gene Therapy
- Cell Therapy
- Stem Cell Therapy
-
- Autologous Therapy
- Allogenic Therapy
- Cell-Based Immunotherapy Products
- Cord Blood/Progenitor Cell Therapies
- Tissue Engineering
- Scaffolds
- Hydrogels
- Collagen
- Others
US Regenerative Medicine Application Outlook
- Musculoskeletal
- Oncology
- Wound Care
- Dental Indications
- Retinal Indications
- Other Applications
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 4.1 Billion |
| Market Size 2023 |
USD 5.3 Billion |
| Market Size 2032 |
USD 39.2 Billion |
| Compound Annual Growth Rate (CAGR) |
28.50% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product, Application, and Region |
| Countries Covered |
US |
| Key Companies Profiled |
Biogen (US), Amgen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Vericel Corporation (US), MiMedx (US), Medtronic plc (US), BioRestorative Therapies, Inc (US), Organogenesis Inc. (US), bluebird bio, Inc. (US), and Athersys, Inc. (US). |
| Key Market Opportunities |
Growing funding for the creation of novel medications |
| Key Market Dynamics |
Increasing chronic illness prevalence in the US Rising rate of use of stem cell technologies in the management of illness |
US Regenerative Medicine Market Highlights:
Frequently Asked Questions (FAQ) :
The US Regenerative Medicine market size was valued at USD 4.1 Billion in 2022.
The market is projected to grow at a CAGR of 28.50% during the forecast period, 2023-2032.
The key players in the market are Biogen (US), Amgen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Vericel Corporation (US), MiMedx (US), Medtronic plc (US), BioRestorative Therapies, Inc (US), Organogenesis Inc. (US), bluebird bio, Inc. (US), and Athersys, Inc. (US).
The cell therapy category dominated the market in 2022.
The musculoskeletal category had the largest share in the market.
